Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Boehringer Ingelheim Limited

First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim and Eko Health Inc. enter digital health collaboration to improve heart murmur detection in dogs
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
From Boehringer Ingelheim Limited
Via GlobeNewswire
Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
From Boehringer Ingelheim Limited
Via GlobeNewswire
Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
New survey shows that over 90% of animal owners trust and appreciate veterinary teams but underestimate the demands of the profession
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim announces succession Chairmen Shareholders’ Committee and Board of Managing Directors
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim launches new trivalent poultry vaccine, includes protection against H5 avian influenza
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer provides update on iclepertin Phase III program in schizophrenia
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
From Boehringer Ingelheim Limited
Via GlobeNewswire
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
From Boehringer Ingelheim Limited
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.